About this trial
Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to water loss, red cell dehydration, and chronic hemolysis. In 90% of cases, it is associated with heterozygous gain-of-function mutations in PIEZO1, a gene that encodes a mechanotransducer responsible for converting mechanical stimuli into biological signals. The remaining 10% of cases are linked to mutations in the GARDOS channel gene.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Any patient diagnosed with hereditary xerocytosis according to the 2021 PNDS guidelines
Covered by a social security plan
Signature of the consent form for study participation by the patient, or for minors, by the parent(s)/legal representative(s).
Disqualifiers
patients with other hemolysis reason
Trial design
Single group
Treatments tested in this trial
Blood sample
Biological/Vaccineblood sample for genetic analysis
Treatment groups
Trial outcomes
Primary outcomes
identification of PIEZO1 mutations
identification of KCNN4 mutations
correlation between the identified PIEZO1 mutations and Hemoglobin levels
correlation between the identified KCNN4 mutations and Hemoglobin levels
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Centre Hospitalier Universitaire, Amiens
Lead sponsor
Kremlin-Bicetre Hospital, Paris
Collaborator